Wei Sang

Featured in: Favicon

wiley.com (+1) Favicon

nature.com Favicon

frontiersin.org Favicon

chemistryworld.com Favicon

jcp.bmj.com Favicon

pubs.acs.org Favicon

Articles

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial - Nature Communications

Apr 20, 2024 | nature.com | Ming Shi |Hongming Huang |Dan Liu |Zhiling Yan |Wei Sang |Kunming Qi | +9 more

AbstractDespite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 CAR T cells targeting BCMA/CD19 and evaluate antimyeloma activity in vitro and in vivo.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →